Menu

Biomedical Research in Endstage & Obstructive Lung Disease (BREATH)

DZL Site Hannover

BREATH Director

Welte 100 100

Prof. Dr. Tobias Welte

Kliniken der Medizinischen Hochschule Hannover
Zentrum Innere Medizin, Abt. Pneumologie
Carl-Neuberg-Str. 1
30625 Hannover
Tel.: +49 (0)511 - 532-3531
Fax: +49 (0)511 - 532-3353
E-Mail: welte.tobias@mh-hannover.de

BREATH Manager

Zurawski 100x100

Dr. Annegret Zurawski

Medizinische Hochschule Hannover
Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), (OE 6876)
Carl-Neuberg-Str. 1
30625 Hannover
Tel.: +49 (0)511 - 532-5192
Fax: +49 (0)511 - 532-18515
E-Mail: zurawski.annegret@mh-hannover.de

Research Profile

The focus of BREATH is the translation of findings from basic research into clinical practice, with regard to all topics listed below. This includes the execution of clinical studies of all phases relevant for registration and with the opening of the Clinical Research Center Hanover in 2015, a joint initiative of the federal government and the State of Lower Saxony, the last gap in this area was closed successfully. Hanover Medical School is one of the three largest Lung Transplantation Centers in the world, and research in End-Stage Lung Diseases is therefore one of the core areas of BREATH. Other closely connected aspects are research on an artificial lung and stem cell  research. Preclinical research is extensively performed in the areas of Infection, Pulmonary Hypertension, Interstitial Lung Diseases as well as Asthma and Allergies. In the area of basic research, BREATH focuses on the pathobiology of bacterial infections of the lung. In cooperation with the Fraunhofer Institute for Toxicology and Experimental Medicine, research is conducted on the pathophysiology of allergic diseases. The Leibniz University adds expertise in health services research and health economic aspects as well as in the area of imaging based on laser techniques. The national research network CAPNETZ aims to improve the patient-centered care for adults and children with Community-Acquired Pneumonia (CAP), and is also involved in the construction of the bronchiectasis registry PROGNOSIS.

Partner Institutions of the Site

chevron-down